Gene Biotherapeutics, Inc. (CRXM)

0.0000 0.0000 (0.00%) As of 03:22PM EDT. Market open.

Gene Biotherapeutics, Inc.

11230 Sorrento Valley Road
Suite 220
San Diego, CA 92121
United States
858 414 1477
https://genebiotherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christopher J. Reinhard	Co-Founder, CEO, President, Treasurer & Director	240k	N/A	1954
Mr. James L. Grainer	Chairman, CFO & Secretary	N/A	N/A	1955
Dr. Lois A. Chandler	Chief Operating Officer	N/A	N/A	1958
Dr. Ronald J. Shebuski	Chief Scientific Officer	N/A	N/A	1953
Mr. Duane Linstrom	General Counsel	119.23k	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Corporate governance

Gene Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.